Trump’s New Tariff Gambit: Slavery Accusations and Drug Price Demands Mask Economic Chaos

Donald Trump refuses to admit defeat. When the Supreme Court ruled his initial tariffs illegal because he invoked fake “emergency powers,” you might have expected him to back off. Instead, the White House is back with a fresh, even more absurd tariff scheme.

The U.S. Trade Commission is holding hearings to find a new legal hook under Section 301 of the Trade Act of 1974. This law lets the president impose tariffs if a foreign country’s trade practices are “unreasonable or discriminatory” and harm U.S. commerce. That sounds reasonable on paper — but the Trump administration’s approach is anything but.

They are investigating dozens of countries, including key allies like the European Union, Canada, Japan, Australia, Mexico, and India, for “forced labor” — a euphemism for slavery. Yes, the White House is seriously considering slapping tariffs on nations like Germany, the UK, Norway, Denmark, and Switzerland based on slavery accusations. These are some of the world’s most ethical countries, ranked far higher than the U.S. in Transparency International’s corruption index.

The logic is shaky at best. Even if slavery isn’t happening in those countries, the administration suggests tariffs could be justified if those countries trade with nations that use forced labor. Trade experts are baffled, calling this a fishing expedition for any excuse to impose tariffs.

Some countries under review, like China and Saudi Arabia, have documented forced labor issues, so scrutiny there is warranted. But lumping in top U.S. allies with spotless labor records exposes this as a political and economic power grab, not a genuine human rights effort.

The administration’s overreach doesn’t stop at slavery claims. They’re also targeting foreign drug pricing policies. The U.S. notoriously allows pharmaceutical companies to charge Americans far higher prices than other developed countries. Now, Trump’s team is demanding countries like the UK raise their drug prices by 25% to match U.S. levels — or face tariffs.

This move would punish countries for protecting their consumers from price gouging, while doing nothing to address the root cause: corporate greed in the U.S. pharmaceutical industry. It’s a brazen attempt to export America’s broken drug pricing to the rest of the world.

The hearings also probe “discrimination” against U.S. tech companies, a thinly veiled attack on the European Union’s new regulations on Big Tech. The administration is weaponizing trade law to retaliate against countries that dare regulate American corporations.

Adding insult to injury, many of the countries targeted by these investigations actually run trade surpluses with the U.S. The administration’s broad-brush approach threatens to spark retaliatory tariffs, escalating trade wars that hurt American workers and consumers.

In short, Trump’s new tariff plan is a reckless, politically motivated fishing expedition. It weaponizes human rights claims and drug pricing policies to justify punishing allies and escalate trade conflicts — all while American families pay the price at the checkout line.

We’ll keep tracking this dangerous gambit and hold the administration accountable for the economic chaos it’s unleashing.